The Royal Free Hospital

Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis–associated pulmonary arterial hypertension: a EUSTAR analysis

OBJECTIVE: Real-world initial treatment strategies in SSc-PAH remain incompletely described. We aimed to characterise these strategies across haemodynamic thresholds and risk strata and evaluate outcome associations. METHODS: We analysed treatment-naïve SSc-PAH patients in EUSTAR...

Nutritional intake on dialysis and non-dialysis days and the effect of intradialytic food provision among hemodialysis patients, a single-center study

Abstract Background/Objectives Patients receiving hemodialysis (HD) are at risk of malnutrition due to the considerable time required to attend dialysis, which may reduce food intake on dialysis days (DDs). We assessed dietary intake on one DD and two non-dialysis days (NDDs) and...

Critical care and the law: Pertinent cases from 2025

This review by the Legal and Ethical Advisory Group (LEAG) follows the 2024 summary, reviewing the important legal cases and Prevention of Future Deaths reports (PFDs) ruled or issued in 2025 that are pertinent to Intensive Care Medicine. The legal cases include Human Rights case...

Addressing evidence gaps in haemodialysis care: a critical review of clinical trials, technological innovations, and implementation priorities

Kidney failure treated with maintenance haemodialysis (HD) carries high risks of premature mortality, hospitalisation and impaired quality of life, yet important evidence gaps persist across routine HD care. The Dialysis Research Innovation Network, part of the UK Kidney Research...

Total intravenous versus volatile anesthesia in living donor hepatectomy: A global prospective cohort study from the international LDLT registry

The choice between total intravenous anesthesia (TIVA) and volatile anesthesia for living donor hepatectomy remains controversial, with limited evidence comparing their impact on donor and recipient outcomes. This study evaluates the association between anesthetic technique and e...

Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy

Importance: Gene-silencing therapies reduce hepatic transthyretin (TTR) production and have been evaluated in phase 3 trials in TTR amyloid cardiomyopathy (ATTR-CM). However, differences in trial design and background therapies have limited assessment of the overall treatment eff...

Plain language summary of how acoramidis affects the total number of heart problems over time in people with ATTR-CM: findings from the ATTRibute-CM study

Plain Language SummaryWhat is this summary about?Transthyretin amyloid cardiomyopathy (ATTR-CM) happens when transthyretin (TTR) protein breaks apart, forming clumps that build up in the heart, making it harder to pump blood.People with ATTR-CM often go to the hospital multiple t...